Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/derm.2023.0024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.
Front Pharmacol
August 2025
Department of Physiology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Type 2 (T2) inflammation underlies a substantial subset of moderate-to-severe asthma, contributing to persistent symptoms and frequent exacerbations. Dupilumab, a fully human immunoglobulin G subclass 4 (IgG4) monoclonal antibody, targets the interleukin-4 receptor alpha (IL-4Rα), thereby inhibiting both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling-which are key cytokines driving T2 inflammation. This review examines the formulation, pharmacological profile, clinical efficacy, safety, and cost-effectiveness of dupilumab in the treatment of asthma, with an emphasis on its role across T2-high and selected T2-low phenotypes.
View Article and Find Full Text PDFBCL-2 Multi-Strain Probiotics for Immunomodulation In Vitro and In Vivo Alleviation of Atopic Dermatitis.
Microorganisms
August 2025
Lotte R&D Center, Seoul 07594, Republic of Korea.
Atopic dermatitis (AD) is a chronic inflammatory disorder with immune imbalance, including elevated IgE levels and mast cell activation mediated by Th2 cytokines, leading to allergic inflammation and impaired skin barrier function. Current treatment limitations highlight the need for safer and more effective AD alternatives. We aimed to evaluate the therapeutic effects of multi-strain probiotics, BCL-2 (comprising LRCC5264 and RAPO), in alleviating AD clinical signs and elucidate its underlying immunomodulatory mechanisms.
View Article and Find Full Text PDFPatient Stratification for Serum LDH Levels Reveals Distinct CLA T-Cell Cytokine Secretion in Response to HDM, Clinical Features and Allergic Comorbidities.
Int J Mol Sci
August 2025
Immunologia Translacional, Departament de Biologia Cellular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), 08028 Barcelona, Spain.
Lactate dehydrogenase (LDH) is a serum biomarker well known to correlate with disease severity in atopic dermatitis (AD). The aim of this study was to explore the cutaneous immune responses and the clinical profile of AD patients in relation to serum LDH levels. To this end, 47 untreated, adult patients with moderate-to-severe AD were stratified by median levels of serum LDH.
View Article and Find Full Text PDFComparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data.
Front Immunol
August 2025
Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Introduction: Molecular targeted therapies, including advanced atopic dermatitis (AD) treatment with Janus kinase 1 inhibitors (JAK1i) and anti-interleukin-13 antibodies (IL-13Ab), are emerging as effective options. However, the predictive biomarkers for treatment responses remain unclear. Therefore, this study compared the short-term efficacy of JAK1i and IL-13Ab and explored relevant biomarkers.
View Article and Find Full Text PDFCanine Alopecia Areata: A Retrospective Study of Clinical, Histopathological Features and Treatments in 14 Dogs.
Vet Dermatol
August 2025
Innovative Vet Path, Leawood, Kansas, USA.
Background: Alopecia areata (AA) is an autoimmune disease resulting in nonscarring hair loss. Limited data are available on the treatment and prognosis of canine AA.
Hypothesis/objectives: The goal of this retrospective study was to describe the clinical and histopathological features and treatment outcomes of 14 canine AA patients.